NetworkNewsBreaks – PreveCeutical Medical Inc. (
Post# of 77
(Total Views: 176)
Posted On: 07/11/2018 5:41:52 PM
NetworkNewsBreaks – PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) Issues Update on Sol-gel Program
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning issued an updated on its soluble gel (“Sol-gel”) drug delivery research and development program, which involves testing an array of cannabis strains for the development and commercialization of cannabinoid-based Sol-gels. Per the update, the program uses five distinct Cannabis sativa L. strains containing an assortment of CBD:THC concentrations, enabling the development of medicinal cannabis products tailored for a broad range of ailments and diseases. The current focus of the Sol-gel program is on preparing formulations containing fixed CBD:THC concentrations that can be utilized with a custom applicator to safely and consistently deliver the compounds to the central nervous system in predefined ratios. As PreveCeutical notes, conventional methods of nasal drug delivery, such as drops and sprays, fail to deliver the therapeutics far enough into the nasal cavity and are rapidly removed by the nose’s self-cleaning mechanisms, decreasing their efficacy. The company’s Sol-gel formulations aim to resolve these issues, making them an ideal vehicle for the nose-to-brain delivery of a host of therapeutic agents.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Health sciences company PreveCeutical Medical Inc. (CSE: PREV) (OTCQB: PRVCF) (FSE: 18H) this morning issued an updated on its soluble gel (“Sol-gel”) drug delivery research and development program, which involves testing an array of cannabis strains for the development and commercialization of cannabinoid-based Sol-gels. Per the update, the program uses five distinct Cannabis sativa L. strains containing an assortment of CBD:THC concentrations, enabling the development of medicinal cannabis products tailored for a broad range of ailments and diseases. The current focus of the Sol-gel program is on preparing formulations containing fixed CBD:THC concentrations that can be utilized with a custom applicator to safely and consistently deliver the compounds to the central nervous system in predefined ratios. As PreveCeutical notes, conventional methods of nasal drug delivery, such as drops and sprays, fail to deliver the therapeutics far enough into the nasal cavity and are rapidly removed by the nose’s self-cleaning mechanisms, decreasing their efficacy. The company’s Sol-gel formulations aim to resolve these issues, making them an ideal vehicle for the nose-to-brain delivery of a host of therapeutic agents.
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)PreveCeutical Medical Inc. (PRVCF) Stock Research Links
Scroll down for more posts ▼